Comparison of receiver operating characteristic (ROC) curves for predicting oral glucose tolerance test (OGTT) 1 h postload glucose ≥155 mg/dL in (A) patients.

Slides:

Advertisements

Similar presentations

Identify the risk factors, diagnosis and prevalence of diabetes in the United States. Describe the function of the pancreas, the intestines and liver.

Advertisements

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.

The 75 g glucose loading test.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Differences in the glycated hemoglobin (HbA1c) levels.

(A) Fasting serum glucose (mg/dL), (B) fasting serum insulin (μU/mL), (C) plasma glycated albumin (GA; %) and (D) plasma fructosamine (μmol/L) measured.

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Prediction and Pathogenesis in Type 1 Diabetes

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Illustration of the causal inference scheme.

Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Suggested pathway for discussions between healthcare professionals and people with diabetes intending to fast during Ramadan. CBG, capillary blood glucose; DVLA,

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Flow sheet over the primary study population as well as comparative individuals of “pre-diabetic” individuals followed from HUNT2 to HUNT3 (GAD, glutamic.

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

Estimated HR as a function of absolute change in glycated hemoglobin (HbA1c; from index to measurement 22–26 months after). Estimated HR as a function.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Mathematical modeling of bubble formation in insulin pump cartridges (3 mL solid line, 2 mL dotted line, and 1.8 mL dashed line) and lines during an increase.

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.

Adjusted annual percentage of quality indicators by prescription

(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

Schematic of screening program for diabetes mellitus (DM) during acute myocardial infarction (AMI). Schematic of screening program for diabetes mellitus.

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Mean and interquartile glucose values for (A) random blood glucose, (B) fastingplasma glucose, (C) HbA1c, (D) 1-hour OGTT, (E) 2-hour OGTT and (F)triglycerides.

Estimated HR as a function of mean residual of glycated hemoglobin (HbA1c) measurements to the line connecting index HbA1c and HbA1c measurement 22–26 months.

Association between antibiotic purchases and glycated hemoglobin (HbA1c) values in patients with and without diabetic nephropathy. Association between.

Enrollment of patients.

Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

(A) Glucose values (mean +SEM) during continuous glucose monitoring while consuming whey protein (solid lines and filled circles) or placebo (broken lines.

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Change in markers of glycometabolism and cardiovascular risk profile.

Interaction of updated mean serial HbA1c and serum triglyceride levels with sensory peripheral neuropathy over 7 years in 151 type 2 diabetic participants.

Participant flow diagram for the ‘GNHIES98—longitudinal sample’ and the ‘DEGS1—cross-sectional sample’. Participant flow diagram for the ‘GNHIES98—longitudinal.

Associations of body mass index (BMI) levels with achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in the upper panels.

Continuous associations

Continuous associations

Receiver-operating characteristic curves showing the performance of the diabetes risk score in predicting diabetes in the United Arab Emirates (UAE) citizens.

The figure shows the mean±SD of glucose and insulin for the 2-hour OGTTs and MTTs for the 12 HP diet subjects and the 12 HC diets subjects. The figure.

Oral glucose tolerance testing during hospitalization and at 4 months after infarction. Oral glucose tolerance testing during hospitalization and at 4 months.

(A) Oral glucose tolerance test (OGTT) glucose and (C) natural logarithm of insulin responses over time with SEM bars comparing the first tertile to the.

Proportion of patients experiencing documented symptomatic hypoglycemia (blood glucose

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

(A) Scatter plot showing the correlation between fasting second void UCPCR and fasting serum C peptide during a 75 g OGTT (rs 0.675, p

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Receiver operator characteristic (ROC) curve for fasting blood glucose (FBG) predicting posttransplantation diabetes (PTD) using time 0 FBG (a) and screening.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

Comparison of receiver operating characteristic (ROC) curves for predicting oral glucose tolerance test (OGTT) 1 h postload glucose ≥155 mg/dL in (A) patients with fasting glucose <100 mg/dL and glycated hemoglobin (HbA1c) <5.7% (N=137, with 33 events); the... Comparison of receiver operating characteristic (ROC) curves for predicting oral glucose tolerance test (OGTT) 1 h postload glucose ≥155 mg/dL in (A) patients with fasting glucose <100 mg/dL and glycated hemoglobin (HbA1c) <5.7% (N=137, with 33 events); the area increased by 0.10 (p=0.059), 0.09 (p=0.087), or 0.17 (p=0.0044) when using fasting glucose, log(HbA1c), or α-hydroxybutyrate (AHB) alone, respectively; or in (B) patients additionally with insulin ≤12 (U/mL, 2 h glucose <140 mg/dL, and a negative antiglutamic acid decarboxylase (anti-GAD) antibody (N=93, with 15 events). The area increased by 0.15 (p=0.016), 0.15 (p=0.038), or 0.24 (p=0.0007), respectively. Stephen A Varvel et al. BMJ Open Diab Res Care 2014;2:e000038 ©2014 by American Diabetes Association